VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-13.82%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.46B
AUM Growth
+$1.46B
(-24%)
Cap. Flow
-$39.6M
Cap. Flow
% of AUM
-2.72%
Top 10 Holdings %
Top 10 Hldgs %
70.47%
Holding
41
New
3
Increased
5
Reduced
10
Closed
4
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$37.7M |
| 2 |
Praxis Precision Medicines
PRAX
|
$21.8M |
| 3 |
Cidara Therapeutics
CDTX
|
$20.6M |
| 4 |
enGene Holdings
ENGN
|
$9.85M |
| 5 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$3.88M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$26.7M |
| 2 |
Merus
MRUS
|
$13.3M |
| 3 |
Terns Pharmaceuticals
TERN
|
$12.9M |
| 4 |
Arvinas
ARVN
|
$11.2M |
| 5 |
Aquestive Therapeutics
AQST
|
$10.4M |
Sector Composition
| 1 | Healthcare | 99.48% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Applied Therapeutics
APLT
$73.7M
| $8.55M | 0.59% |
9,990,591
+165,591
| +2% | +$142K |
|
|
PCSC
27
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.64M | 0.52% |
750,000
| – | – |
|
|
28
Terns Pharmaceuticals
TERN
$651M
| $5.97M | 0.41% |
1,077,090
-2,332,968
| -68% | -$12.9M |
|
29
Taysha Gene Therapies
TSHA
$791M
| $5.58M | 0.38% |
3,225,180
-5,774,820
| -64% | -$9.99M |
|
30
Trevi Therapeutics
TRVI
$871M
| $5.22M | 0.36% |
1,266,457
-2,156,199
| -63% | -$8.88M |
|
31
Zura Bio
ZURA
$132M
| $5.06M | 0.35% |
2,023,166
| – | – |
|
32
Century Therapeutics
IPSC
$40.4M
| $4M | 0.27% |
3,957,186
-1,432,073
| -27% | -$1.45M |
|
33
CASI Pharmaceuticals
CASI
$36.1M
| $2.79M | 0.19% |
987,259
| – | – |
|
34
Tenaya Therapeutics
TNYA
$192M
| $2.22M | 0.15% |
1,555,556
| – | – |
|
35
Tenax Therapeutics
TENX
$27.5M
| $1.29M | 0.09% |
208,333
| – | – |
|
|
CBIO
36
Crescent Biopharma, Inc. Common Stock
CBIO
$184M
| $747K | 0.05% |
+3,000,000
| New | +$747K |
|
37
Instil Bio
TIL
$196M
| $633K | 0.04% |
33,177
| – | – |
|
|
38
Edgewise Therapeutics
EWTX
$1.54B
| – | – |
-1,000,000
| Closed | -$26.7M |
|
39
Cabaletta Bio
CABA
$144M
| – | – |
-1,563,952
| Closed | -$7.38M |
|
|
40
Arvinas
ARVN
$580M
| – | – |
-454,450
| Closed | -$11.2M |
|
41
Adverum Biotechnologies
ADVM
$68.2M
| – | – |
-1,467,048
| Closed | -$10.3M |
|